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Abstract 
Background: In critically ill children, in‑line microfilters may reduce the incidence of the systemic inflammatory 
response syndrome (SIRS), the overall complication and organ dysfunction rate. No data on the use of in‑line microfil‑
ters exist in critically ill adults.
Methods: In this prospective, randomized, controlled open‑label study, we evaluated the influence of in‑line 
microfilters on systemic immune activation in 504 critically ill adults with a central venous catheter in place and an 
expected length of stay in the intensive care unit >24 h. Patients were randomized to have in‑line microfilters placed 
into all intravenous lines (intervention group) or usual care (control group). The primary endpoint was the number 
of intensive care unit days with SIRS. Secondary endpoints were the incidence of SIRS, SIRS criteria per day, duration 
of invasive mechanical ventilation, intensive care unit length of stay, the incidence of acute lung injury, maximum 
C‑reactive protein, maximum white blood cell count, incidence of new candida and/or central‑line‑associated blood‑
stream infections, incidence of new thromboembolic complications, cumulative insulin requirements and presence of 
hyper‑ or hypoglycemia.
Results: The study groups did not differ in any baseline variable. There was no difference in the number of days in 
the intensive care unit with SIRS between microfilter and control patients [2 (0.8–4.7) vs. 1.8 (0.7–4.4), p = 0.62]. Except 
for a higher incidence of SIRS in microfilter patients (99.6 vs. 96.8 %, p = 0.04), no difference between the groups was 
observed in any secondary outcome parameter. Results did not change when only patients with an intensive care 
unit length of stay of greater than 7 days were included in the analysis. The rate of adverse events was comparable 
between microfilter and control patients. In two patients allocated to the microfilter group, the study intervention 
was discontinued for technical reasons. Use of in‑line microfilters was associated with additional costs.
Conclusions: The use of in‑line microfilters failed to modulate systemic inflammation and clinical outcome param‑
eters in critically ill adults.
Trial registration: Clinical Trials NCT01534390
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Background
Injection or infusion of drugs and fluids releases micro-
particles into the bloodstream [1, 2]. Particulate contami-
nation arises from manufacture, packaging and transport 
of solutions and drugs [3] or drug incompatibility reac-
tions [4]. These particles may stimulate the immune sys-
tem and cause organ damage, thus aggravating the 
underlying disease [5]. As a pro-inflammatory state com-
monly occurs during critical illness [6], patients in the 
intensive care unit (ICU) may be specifically vulnerable 
to particle infusion and additional immune stimulation 
[3]. Systemic stimulation of the immune system in criti-
cally ill patients is a risk factor for multiple organ dys-
function and death [6]. Mechanisms of particle-induced 
organ damage are a mechanical blockage of microvessels 
[3], the activation of platelets and neutrophilic granulo-
cytes with the generation of occlusive micro-thrombi [3] 
and the formation of foreign body granulomas [7–9].
In-line microfilters are placed in the infusion lines and 
were first used in the 1960s to avoid particle exposition of 
patients during intravenous drug therapies [7, 10]. Since 
then, in-line microfilters have repeatedly been shown to 
prevent particles from being introduced into the blood-
stream [11]. In-line microfilters with small enough pores 
may even retain certain microorganisms, such as large 
bacteria and fungal spores, endotoxins and air [12]. In 
807 critically ill children, use of in-line microfilters was 
associated with a reduction in the overall complication 
rate and incidence of the systemic inflammatory response 
syndrome (SIRS) [13]. The same study group showed that 
in-line filtration had beneficial effects on the preserva-
tion of hematologic, renal and respiratory function in 
critically ill children [14]. While other authors confirmed 
these positive results in critically ill children and neo-
nates [9, 15, 16], no data on the use of in-line microfilters 
exist in critically ill adults.
In this prospective, randomized, controlled open-label 
trial, the influence of in-line microfilters on systemic 
immune activation was evaluated. We hypothesized that 
the use of in-line microfilters reduces the number of days 
with SIRS.
Methods
This study was designed as a single-center, prospective, 
randomized, controlled, open-label trial. It was con-
ducted in a 22-bed interdisciplinary ICU of a tertiary care 
university teaching hospital during the time from April 
2012 to August 2013. The study protocol was approved 
by the Ethics Committee of the Land Salzburg (415-
E/1442/7-2012). Written informed consent was obtained 
from all patients or their legal representatives. The trial 
was registered at the Clinical Trials database of the US 
National Institutes of Health (trial registration number, 
NCT01534390; https://clinicaltrials.gov/ct2/show/NCT0 
1534390; date of registration: February 9, 2012).
Patients and randomization
All critically ill patients older than 18  years with an 
expected length of stay in the ICU > 24 h and a central 
venous catheter in place or one placed within the first 
24  h after ICU admission were eligible for study entry. 
Patients who did not meet any exclusion criteria were 
randomly assigned into a study and a control group using 
a computer-generated randomization list. Age < 18 years, 
pregnancy, neutropenia (<  1.5 G/L) or known immu-
nosuppression, limited intensive care, inclusion into 
another clinical trial, and refusal of written informed 
consent were considered exclusion criteria. In case 
patients were re-admitted to the ICU, they were enrolled 
in the study only during their first ICU stay.
Study intervention
In patients allocated to the study group, in-line micro-
filters were placed into all intravenous lines as soon as 
possible following ICU admission. Patients assigned to 
the control group received usual care. Study group allo-
cation was retained for the entire ICU stay. The in-line 
microfilters used (MedCare; Oberwang, Austria) had 
a pore size of 0.2 or 1.2 µm and consisted of polyether-
sulfone membranes with a low adsorption profile (for 
maximum transmission of proteins and extensive drug 
compatibility). All products used were approved for 
intravenous therapy and CE-certified (Supor IV Filter®; 
Pall Corporation, Port Washington, NY, USA). Accord-
ing to an institutional algorithm, in-line microfilters 
were introduced into each lumen of venous catheters. 
0.2 µm pore size positively charged filters were used for 
aqueous solutions and 1.2 µm pore size filters for infu-
sion of lipid-containing admixtures. Because of the small 
pore size and the resulting reduction of flow, all intrave-
nous solutions were administered by infusion or syringe 
pumps. In emergency cases, when rapid fluid infusions 
or blood transfusions were required, in-line microfilters 
could be bypassed by administering fluids and blood 
products via a three-way cock placed into the infusion 
line following the microfilters. According to an institu-
tionally standardized colour scheme, different infusion 
lines were used for special medications to prevent drug 
incompatibility (Fig.  1). 1.2  µm filters were replaced 
daily, while 0.2 µm filters were replaced following 72 h of 
regular use.
Data collection and definitions
At study entry, demographic data, comorbidities and 
the admission diagnosis were collected. The presence of 
SIRS, as defined by the ACCP/SCCM criteria [17], was 
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documented daily-based electronic data documentation 
(MetaVision®; IMDSoft, Tel Aviv, Israel) at 1-min inter-
vals of heart rate, core temperature and respiratory rate, 
as well as once daily measurement of the white blood cell 
count. During the study period, patients were screened 
for specific therapies (blood transfusion, vasopressor 
therapy, invasive mechanical ventilation, renal replace-
ment or extracorporeal membrane oxygenation therapy), 
occurrence of acute lung injury or the acute respiratory 
distress syndrome [18], candida bloodstream infection, 
central-line-associated bloodstream infection, any new 
thromboembolic complication, presence of hyper- (blood 
glucose level > 180 mg/dL) or hypoglycemia (blood glu-
cose level  <  75  mg/dL), as well as the need for insulin 
therapy and cumulative insulin requirements during the 
ICU stay. At ICU discharge, the maximum C-reactive 
protein serum concentration and white blood cell count 
during the ICU stay were documented. In addition, dura-
tion of invasive mechanical ventilation, length of ICU 
stay, and the survival status at ICU discharge were col-
lected. In patients randomized to the in-line microfilter 
group, additional costs arising from the use of in-line 
microfilters were calculated.
Primary and secondary study endpoints
The primary study endpoint was the number of ICU 
days with SIRS. Secondary study endpoints were the 
incidence of SIRS, the number of SIRS criteria per day 
with the syndrome, the duration of invasive mechanical 
ventilation, the length of stay in the ICU, the incidence 
of acute lung injury/acute respiratory distress syndrome, 
the maximum C-reactive protein serum concentration, 
the maximum white blood cell count, the incidence of 
new candida and/or central-line-associated bloodstream 
infections, the incidence of new thromboembolic com-
plications, cumulative insulin requirements and presence 
of hyper- or hypoglycemia.
Statistical analysis
We estimated that a sample size of 504 patients (252 per 
study group) would provide an 80  % power to detect 
a reduction in the number of ICU days with SIRS from 
Fig. 1 Schematic overview of different sized and colored in‑line filters on a central venous catheter
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2  ±  2  days by 0.5  days to 1.5  ±  2  days at a two-sided 
alpha-error of 5 %. All statistical analyses were based on 
the intention-to-treat principle. No blinding of outcome 
assessment was performed. Normality distribution of 
the study variables was tested with Shapiro–Wilks tests 
and was approximately fulfilled in all study parameters. 
Comparisons between the study and control group were 
performed using the Mann–Whitney U- or Fisher’s 
Exact test, as appropriate. In a post hoc analysis, we 
repeated the comparisons of primary and secondary 
outcome parameters between study and control patients 
in a selected population of patients with an ICU length 
of stay >7  days. All tests were two-sided, and a p value 
<0.05 was considered to indicate statistical significance. 
Quantitative data are expressed as median values with 
interquartile ranges, qualitative data as numbers and 
percentages. The IBM SPSS Statistics software was used 
for statistical analysis (IBM SPSS Statistics 20; Erlangen, 
Germany).
Results
Of 1716 patients screened for study eligibility, 504 
patients were enrolled in the trial. No patient was lost 
to follow-up (Fig.  2). The study groups did not differ in 
demographic data, comorbidities, admission diagnoses 
or other clinical data (Table 1). There was no difference 
in the number of days in the ICU with SIRS between 
microfilter and control patients. Except for a higher inci-
dence of SIRS in in-line microfilter patients, no difference 




expected ICU LOS <24 hrs (n=701)
no central venous catheter (n=426)
ICU re-admissions (n=36)
neutropenia/immunesuppression (n=34)
age <18 years (n=8)
denial of wrien consent (n=7)
randomized
(n=504)








lost to follow-up (n=0)
disconnued 
intervenon (n=2)
lost to follow-up (n=0)
Fig. 2 Overview of patient enrollment. ICU intensive care unit, LOS length of stay
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parameter. The results did not change when only patients 
with an ICU length of stay of greater than 7 days were 
included in the analysis (Table  2). The maximum white 
blood cell count and maximum C-reactive protein serum 
concentrations did not differ between the groups (Fig. 3). 
The rate of adverse events was comparable between 
microfilter and control patients (Table 3). In two patients 
allocated to the in-line microfilter group, the study inter-
vention was discontinued. In one patient, a leakage of 
propofol occurred from the in-line microfilter leading to 
inadequate sedation and patient-ventilator dyssynchrony. 
In the other patient, the three-way cock proximal of the 
in-line microfilter was missing and rescue fluids could 
only be administered at a too low velocity. The use of 
in-line microfilters in the study group resulted in addi-
tional median costs per patient of 54.7 (54.7–109.4) € and 
25 544.9 € for the entire study group.
Discussion
In this randomized, controlled open-label trial, we could 
not confirm our hypothesis that in-line microfilters 
reduce the number of ICU days with SIRS in the adult 
critically ill patients. In addition, no differences in other 
markers of immune activation, the rate of acute lung 
injury or the acute respiratory distress syndrome, dura-
tion of mechanical ventilation, ICU length of stay, and 
ICU mortality were observed. The results did not change 
when including only patients with an ICU length of stay 
of greater than 7 days. Adverse events occurred at a simi-
lar rate in patients with and without in-line microfilter 
use. The use of in-line microfilters was associated with 
additional costs.
Similar to the study proving the beneficial effects of 
in-line microfilters in critically ill children [13], we used 
the incidence, duration and extent of SIRS as the main 
indicator of systemic immune activation and primary 
study endpoint in this study. Since three of four SIRS cri-
teria were documented electronically at 1-min intervals, 
almost all study patients fulfilled the non-time-related 
SIRS criteria at least once during their ICU stay. There-
fore, the very high rate of SIRS in this patient population 
is likely to have over-estimated the true incidence of SIRS 
due to systemic inflammation as some increases in heart 
and respiratory rate may have simply reflected physical 
activity or resulted from nursing care. As the serum con-
centrations of the C-reactive protein and the white blood 
cell count are typically not influenced by the above-men-
tioned factors, it seems prudent to use these parameters 
as a more reliable marker of immune activity than SIRS 
in this closely monitored patient population. Both the 
C-reactive protein and white blood cell count reflect sys-
temic inflammation in the critically ill [19, 20].
Although the efficacy of in-line microfilters to prevent 
particles from entering the bloodstream was not tested in 
our study, several previous reports confirmed this ability 
of the microfilters used in our study [13–15]. Interest-
ingly, despite the fact that one can assume that infusion 
of microparticles was reduced in the intervention group, 
no difference in clinical or laboratory signs of immune 
activation could be detected between patients with and 
without in-line microfilter care. Consequently, outcome 
parameters associated with systemic inflammation, such 
as acute lung injury, duration of mechanical ventilation, 
length of ICU stay and ICU mortality [21], were com-
parable between the study groups. As the number of 
ICU days with SIRS observed in this study population 
matched well with what the power analysis had been 
based on, it is unlikely that our trial was underpowered 
to detect a significant difference between groups in this 
study population. Our data suggest that filtration of par-
ticles from injections and infusions by in-line microfilters 
does not modulate the systemic immune response in the 
adult critically ill patients and cannot prevent acute lung 
injury or reduce the duration of mechanical ventilation. It 
can be debated what role particles played that were intro-
duced into the bloodstream by rescue fluids administered 
proximal to the in-line microfilters.
Table 1 Patient characteristics






Age (years) 66.5 (56–76) 68 (58–77) 0.33
Male gender (n/%) 151 (59.9) 145 (57.5) 0.65
BMI (kg/m2) 26 (23–30) 25 (23–29) 0.35
Comorbidities (n/%)
 Chronic arterial hyperten‑
sion
101 (40.1) 96 (38.1) 0.71
 Coronary artery disease 36 (14.3) 25 (9.9) 0.17
 Congestive heart failure 31 (12.3) 26 (10.3) 0.57
 COPD 50 (19.8) 46 (18.3) 0.73
 Diabetes mellitus 32 (12.7) 35 (13.9) 0.79
 Malignancy 58 (23.0) 53 (21.0) 0.67
Admission diagnoses (n/%)
 Abdominal surgery 72 (28.6) 62 (24.6) 0.36
 Cardiovascular surgery 40 (15.9) 43 (17.1) 0.81
 Trauma 26 (10.3) 25 (9.9) 1
 Other surgery 52 (20.6) 48 (18.3) 0.74
 Medical condition 62 (24.6) 76 (30.1) 0.19
Blood transfusion (n/%) 86 (34.1) 78 (31.0) 0.51
Vasopressor therapy (n/%) 163 (64.7) 158 (62.7) 0.71
Invasive mechanical venti‑
lation (n/%)
123 (48.8) 114 (45.2) 0.47
Replacement therapy (n/%) 24 (9.5) 26 (10.3) 0.88
ECMO therapy (n/%) 5 (2.0) 5 (2.0) 1.00
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Our results are in contrast to the observations made 
with the use of in-line microfilters in critically ill children, 
in whom beneficial effects on hematologic, renal and res-
piratory function were reported [14, 16]. Using a compa-
rable study design, a randomized, controlled open-label 
trial including 807 pediatric ICU patients revealed that 
the use of in-line microfilters decreased the incidence of 
SIRS, the length of ICU stay, and the duration of mechan-
ical ventilation [13]. Similar to our study, the same type 
of in-line microfilters, a standardized infusion regi-
men and identical standards of filter care were applied. 
These similarities in the design and intervention suggest 
Table 2 Primary and secondary outcome parameters
SIRS, systemic inflammatory response syndrome; ALI/ARDS, acute lung injury/acute respiratory distress syndrome; ICU, intensive care unit
* Significant difference between groups






 n 252 252
Primary outcome parameter
 Days with SIRS (days) 2 (0.8–4.7) 1.8 (0.7–4.4) 0.62
Secondary outcome parameters
 Patients with SIRS (n/%) 251 (99.6) 244 (96.8) 0.04*
 SIRS criteria per SIRS day (n) 2 (2–2) 2 (2–3) 0.77
 New ALI/ARDS (n/%) 8 (3.2) 6 (2.4) 0.77
 Duration of invasive mechanical ventilation (days) 0.5 (0.1–2) 0.8 (0.3–2.7) 0.14
 Length of stay in the ICU (days) 2.3 (1–5.2) 2 (1–4.7) 0.53
 ICU mortality (n/%) 30 (11.9) 28 (11.1) 0.89
Post hoc analysis: ICU stay > 7 days
 n 37 35
 Days with SIRS (days) 8 (6–16) 9 (6–17) 0.76
 Patients with SIRS (n/%) 37 (100) 35 (100) 1
 SIRS criteria per SIRS day (n) 2 (2–3) 2 (2–3) 0.89
 New ALI/ARDS (n/%) 7 (18.9) 4 (11.4) 0.52
 Duration of invasive mechanical ventilation (days) 4 (1–10) 5 (3–9) 0.89
 Length of stay in the ICU (days) 10 (8–17) 12 (9–19) 0.64
 ICU mortality (n/%) 9 (24.3) 5 (14.3) 0.38
Fig. 3 Differences in the maximum white blood cell count and C‑reactive protein levels between study groups
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that differences between ours and the pediatric stud-
ies could result from a different inflammatory response 
of critically ill children to particle infusion compared 
to adults. On the other hand, one needs to consider the 
possibility that the positive findings of the pediatric trial 
may have reflected a type I error given its single-center 
and unblinded design. Interestingly, a recent Cochrane 
meta-analysis on the use of intravenous in-line filters in 
neonates included four trials with a total of neonates. 
No difference in overall mortality, proven and suspect 
septicemia or other secondary outcomes such as local 
phlebitis, thrombosis, necrotizing enterocolitis, duration 
of cannula patency, length of hospital stay, number of 
catheters inserted and financial costs was detected [22]. 
Unlike the pediatric studies, we did not evaluate specific 
extra-pulmonary organ functions such as renal or hema-
tologic function. Yet, it is unlikely that we have missed a 
clinically relevant difference in these organ functions as 
this would have probably affected the length of ICU stay 
or other outcome parameters [23].
The rate of adverse events was a secondary endpoint of 
this trial. Due to their physical ability, in-line microfilters 
may theoretically bind drugs such as heparins, insulin, 
and others. As no difference in the rate of new throm-
boembolic complications, glycemic derangements, and 
cumulative insulin requirements was observed between 
groups, it can be assumed that drug binding by in-line 
microfilters occurs, if at all, at a clinically irrelevant 
extent. On the other hand, our study failed to show any 
beneficial effects which could result from the use of in-
line microfilters as for example filtering of bacteria and 
yeasts. Accordingly, the rate of central-line-associated 
bloodstream infections and new candidemia was compa-
rable between the study groups.
Certain limitations need to be considered when inter-
preting the results of this study. We applied a non-
blinded design as we did not use sham filters. Even 
though voluntary contamination of injections or infu-
sions with particles is unlikely to have occurred, we can-
not exclude that a risk of bias has been introduced by 
choosing an unblinded design [24]. Another limitation 
is that we selected 504 out of 1716 patients screened. An 
expected ICU stay <24 h and no central venous catheter 
in place were the most common reasons for exclusion. 
Therefore, the results of our study cannot be extrapo-
lated to patients with an ICU stay <24 h. Finally, this trial 
was conducted in a single center and included a mixed 
critically ill adult patient population. We do not know 
whether different results would have been observed had 
the trial been performed in several centers or had only 
selected patient populations been included [25].
Conclusions
In conclusion, the use of in-line microfilters failed to 
modulate systemic inflammation and clinical outcome 
parameters in adult critically ill patients.
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New thromboembolic event (n/%) 1 (0.4) 3 (1.2) 0.62
Patients with hyperglycemia (n/%) 109 (43.3) 121 (48) 0.33
Insulin therapy (n/%) 91 (36.1) 104 (41.3) 0.27
Cumulative insulin dose (IU) 58 (18–136) 53 (22–207) 0.95
Patients with hypoglycemia (n/%) 27 (10.7) 19 (7.5) 0.28
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